Summary
The present study aimed to investigate the effect of roxithromycin on the oral and intravenous pharmacokinetics of loratadine in rats. The pharmacokinetic parameters of loratadine were measured after an orally (4 mg/kg) and intravenously (1 mg/kg) administration of loratadine in the presence or absence of roxithromycin (2.0 or 5.0 mg/kg). Compared with the control (given loratadine alone), the area under the plasma concentration-time curve (AUC) was significantly (2.0 mg/kg,P<0.05; 5.0 mg/kg,P<0.01) increased by (76.8–119.2)% in the presence of roxithromycin after oral administration of loratadine. The peak plasma concentration (C max) was significantly (2.0 mg/kg,P<0.05; 5.0 mg/kg,P<0.01) increased by (45.1–97.6)% in the presence of roxithromycin after oral administration of loratadine. Consequently, the relative bioavailability (R.B.) of loratadine was increased by 1.77-to 2.19-fold. In contrast, roxithromycin had no effect on any pharmacokinetic parameters of loratadine given intravenously. It suggested that roxithromycin may improve the oral bioavailability of loratadine by reducing first-pass metabolism of loratadine most likely mediated by P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 in the intestine and/or liver. In conclusion, the presence of roxithromycin significantly enhanced the bioavailability of loratadine in rats, it may be due to inhibition of both CYP 3A4-mediated metabolism and P-gp in the intestine and/or liver by the presence of roxithromycin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Markcham A., Faulds D. (1994): Roxithromycin. An update of its antimicrobial activity, pharmacoinetic properties and therapeutic use. Drugs, 48, 297–326.
Young R.A., Gonzalez J.P., Sorkin E.M. (1989): Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs, 37, 8–41.
Ledirac N., de Sousa G., Fontaine F., Agouridas C., Gugenheim J., Lorenzon G., Rahmani R. (2000): Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab. Dispos., 28, 1391–1393.
Yamazaki H., Shimada T. (1989): Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab. Dispos., 26, 1053–1057.
Benet L.Z., Cummins C.L., Wu C.Y. (2003): Transporterenzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 4, 393–398.
Zhang Y., Guo X., Lin E.T., Benet L.Z. (1998): Overlapping substrate specificities of cyt-ochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab. Dispos., 26, 360–366.
Pachot J.I., Botham R.P., Haegele K.D., Hwang K. (2003): Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci., 6, 1–12.
Bradley C.M., Nicholson A.N. (1987): Studies on the central effects of the H1-antagonist, loratadine. Eur. J. Clin. Pharmacol., 32, 419–421.
Ramaekers J.G., Uiterwijk M.M., O’Hanlon J.F. (1992): Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during d-riving. Eur. J. Clin. Pharmacol., 42, 363–369.
Kay G.G., Berman B., Mockoviak S.H., Morris C.E., Reeves D., Starbuck V., Sukenik E., Harris A.G. (1997): Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch. Intern. Med., 157, 2350–2356.
Philpot E.E. (2000): Safety of second generation antihistamines. Allerg. Asthma. Proc., 21, 15–19.
Prenner B.M., Capano D., Harris A.G. (2000): Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: adouble-blind comparison with crossover treatment of nonresponders. Clin. Ther., 22, 760–769.
Clissold S.P., Sorkin E.M., Goa K.L. (1989): Loratadine, a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 37, 42–57.
Hilbert J., Radwanski E., Weglein R., Luc V., Perentesis G., Symchowicz S., Zampaglione N. (1987): Pharmacokinetics and dose proportionality of loratadine. J. Clin. Pharmacol., 27, 694–698.
Kreutner W., Hey J.A., Anthes J., Barnett A., Young S., Tozzi S. (2000): Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 50 345–352.
Henz B.M. (2001): The pharmacologic profile of desloratadine: a review. Allergy, 56 Suppl 65, 7–13.
Yumibe N., Huie K., Chen K.J., Snow M., Clement R.P., Cayen M.N. (1996): Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol., 51, 165–172.
Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. (2001): Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos., 29, 1080–1083.
Wacher V.J., Silverman J.A., Zhang Y., Benet L.Z. (1998): Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322–1330.
Ito K., Kusuhara H., Sugiyama Y. (1999): Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption; theoretical approach. Pharm. Res., 16, 225–231.
Pichard L., Gillet G., Fabre I., Dalet-Beluche I., Bonfils C., Thenot J.P., Maurel P. (1990): Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos., 18, 711–719.
Carr R.A., Edmonds A., Shi H., Locke C.S. Gustavson L.E., Craft J.C., Harris S.I., Palmer R. (1998): Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob. Agents Chemother, 42, 1176–1180.
Kosoglou T., Salfi M., Lim J.M., Batra V.K., Cayen M.N., Affrime M.B. (2000): Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br. J. Clin. Pharmacol., 50, 581–589.
Yin O.Q., Shi X., Chow M.S. (2003): Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 796, 165–172.
Amini H., Ahmadiani A. (2004): Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 809, 227–230.
Cummins C.L., Jacobsen W., Benet L.Z. (2002): Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036–1045.
Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. (2000): Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 10, 1439–1443.
Kaminsky L.S., Fasco M.J. (1991): Small intestinal cytochromes P450. Crit. Rev. Toxocol., 21, 407–422.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, C., Kim, CS., Yang, JY. et al. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Eur. J. Drug Metabol. Pharmacokinet. 33, 231–236 (2008). https://doi.org/10.1007/BF03190877
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190877